Insulin is now well established as an adiposity signal that acts in the brain to influence energy homeostasis. It is secreted in direct proportion to adiposity; it enters the brain from the blood, and it interacts with neurons in the ventral hypothalamus. Experimental manipulation of brain insulin causes predictable changes of food intake and body weight. Because insulin shares many properties with other adiposity signals, especially leptin, in this regard, it is important to recognize the similarities and differences in the signal each conveys to the brain in order to design effective therapeutic approaches to treat pathologies of eating and body weight.
Introduction
Twenty-five years ago, Woods and Porte proposed that insulin passes from the blood to the cerebrospinal fluid (CSF) and on into the brain, where it provides a signal related to the amount of fat in the body. 1, 2 The evidence supporting this contention was largely circumstantial at that time, relying upon several inter-related observations. The lynchpin was that both basal and stimulated insulin levels directly correlate with body adiposity, 3 such that plasma insulin is a reliable index of body fat. Although there is no evidence that the brain itself synthesizes insulin, 4 both the brain and the CSF contain immunoreactive insulin, and CSF insulin levels are higher in obese than in lean individuals. 4, 5 Thus, the logical conclusion was that brain insulin was derived from circulating insulin. Consistent with a central site of action for insulin, insulin binding sites are localized in discrete brain areas, 5 many in areas known to be important in energy homeostasis and in close proximity to the cerebral ventricles.
The original hypothesis
The hypothesis proposed in the 1970s was simple and prescient. Woods and Porte suggested that insulin acts within the brain to cause a long-term, net catabolic response, decreasing food intake and increasing energy expenditure. 1, 2 Hence, prolonged exposure of the brain to exogenous insulin would lead to a loss of body weight. The belief at the time was that the likely route for plasma insulin to penetrate the brain was via the choroid plexus into the CSF and subsequently through the ependymal lining to reach nearby receptors on neurons. Since the choroid plexus is rich with insulin-binding sites, 5 since several nuclei in the ventral hypothalamus lie very close to the third ventricle, and since insulin binding is particularly dense in the ventral hypothalamus (see above), circumstantial evidence supported the contention. Hence, insulin was seen as the best (in fact, the only viable) candidate to be the long-sought signal that Kennedy had postulated as the basis of his lipostatic hypothesis. 6 The subsequent demonstration that the infusion of insulin directly into the CSF of baboons caused a dose-dependent reduction of food intake and body weight was consistent with the model. 2 While time has proven the overall hypothesis to have considerable merit, several specifics have changed. While many groups found that systemically administered insulin gets into the CSF, the exact route of entry was brought into question by two key findings. The first is that most insulinbinding sites are on the CSF rather than the plasma side of the choroid plexus, 5 suggesting that if receptor-mediated movement of insulin occurred, it would be likely to be from CSF to blood. The second was the demonstration that brain capillary endothelial cells contain insulin receptors as well as the necessary intracellular apparatus to transport insulin from blood to brain interstitial fluid. 4 Schwartz and his colleagues subsequently found that the transport of insulin into the brain is receptor-mediated and saturable, and that its entry into the CSF follows the kinetics dictated by a three-compartment model (ie blood to brain to CSF) rather than a two-compartment model (ie blood to CSF). 4 The question was then raised as to how it is that when exogenous insulin is administered into the cerebral ventricles, it is effective. The answer appears to be that, when exogenous insulin is administered into the CSF and behavioral and physiological effects are observed, the insulin goes against the normal flow of fluid and diffuses into the neuropil to reach nearby receptors. 7 Consistent with this, when insulin has been administered directly into regions of the ventral hypothalamus, it has reduced food intake and body weight at lower doses than are required when it is given into the CSF. 8, 9 Insulin as an adiposity signal to the brain Several groups have systematically varied the dose of exogenous insulin administered into the ventricles (ivt) of rats and found that higher doses cause proportionally greater anorexia and weight loss. 10 Manipulation of the maintenance diet has revealed that ivt insulin is less efficacious when a higher proportion of fat is consumed, 11, 12 and our group further found that central insulin selectively reduces dietary fat intake (and=or protects carbohydrate intake). 9, 12 Because a decrease of food intake is symptomatic of ill or distressed animals, we completed a rigorous series of control experiments that ruled out the possibility that the hypophagia caused by central insulin is secondary to illness or incapacitation. 13 In parallel experiments we provided strong evidence that an increase of insulin in the brain lowers the body weight a rat is willing to maintain and defend.
14 Although in most experiments insulin has been infused via osmotic minipump into the third cerebral ventricle, it has also been administered directly into the hypothalamic arcuate nuclei (ARC) and adjacent areas of the ventral hypothalamus with analogous results. 10 While many groups have found that administering exogenous insulin into the third ventricle (i3vt) of rats reduces food intake and body weight, achieving the converse situation has been more difficult, ie reducing endogenous insulin activity in the brain to determine whether energy intake actually increases. Documenting a normal role for endogenous insulin at its brain receptor is key to the overall hypothesis. Several years ago it was found that the administration of insulin antibodies into the ventral hypothalamus increases food intake and body weight, 8, 15 but experiments in which diluted sera are administered into the brain are difficult to interpret cleanly. Ideally, specific antagonists to the insulin receptor could be administered, but no such compounds exist. A novel approach, using sophisticated techniques for modifying the genome of cells, has recently been applied by Kahn's group. 16 They created mice with brain-specific disruption of the insulin receptor gene. As adults, females were hyperphagic and both genders became more obese than wild-type mice when fed a high-fat diet. However, both genders also had reduced fertility, such that it is possible that all or part of the obesity syndrome is secondary to hypogonadism. Perhaps analogous to the experiments on insulin receptor knockout mice, transgenic mice with increased central insulin signaling are resistant to dietinduced obesity. 17 All of these reports support the hypothesis that endogenous insulin signaling in the brain is directly involved in the regulation of energy balance.
Insulin within the brain
Schwartz and his colleagues completed a series of studies on dogs, working out the parameters of the receptor-mediated, saturable transport system that moves insulin from the circulation into the brain; and there is strong evidence that a homologous system exists in other species including humans and rats. 4, 10 Related to this, we recently found that dogs whose transport of insulin across the blood -brain barrier remains high when they are changed from a low-fat to a high-fat diet are not susceptible to developing dietinduced obesity, whereas dogs who do not transport insulin as efficiently into the brain become obese. 18 Importantly, the degree of high-fat diet-induced obesity is proportional to the change of insulin transport into the brain. Hence, regulation of the rate of transport of insulin through the blood -brain barrier may be a key factor in the susceptibility to dietinduced obesity.
Baskin and his colleagues have mapped the location of central insulin binding sites and insulin receptor mRNA. Although many areas of the brain not thought to be directly involved in energy homeostasis contain insulin receptors, particularly high concentrations are localized in the hypothalamus and especially in the arcuate nuclei. In particular, we have previously observed insulin receptors on arcuate cells that synthesize neuropeptide Y (NPY) 19, 20 and we have more recently observed that arcuate neurons that synthesize proopiomelanocoritin (POMC) also contain insulin receptors (unpublished observations).
Consistent with all of these observations, the tubby mouse has recently been found to have a mutation in the intracellular insulin-signaling pathway within some cells in the ventral hypothalamus. 21 The tubby mouse has a naturally occurring mutation in the tub gene and is characterized by hyperphagia and obesity (as well as visual and hearing deficits). Importantly, targeted deletion of tub results in an apparently identical phenotype, suggesting that the tubby mouse has a loss-of-function mutation. Key to the present discussion, besides being expressed in the cochlea and retina, tub is expressed in neurons in several nuclei in the ventral hypothalamus including the ARC. Finally, and relevant to the discussion below on ARC neuropeptides, tubby mice have reduced POMC mRNA in the ARC and increased NPY mRNA in the dorsomedial and ventromedial hypothalamic nuclei.
Hence, in some ways the tubby mouse is analogous to the db=db mouse which has mutated leptin receptors; both have reduced signaling of important adiposity peptides in the brain and both are hyperphagic and obese. An important difference is that, unlike the leptin receptor gene, the tub gene is normally expressed only in specific neuronal populations. The experiments on tubby mice therefore also suggest that endogenous insulin normally acts within the hypothalamus to reduce body weight. In sum, insulin is now well established as an adiposity signal to the brain.
Leptin as an adiposity signal
Leptin, the new kid on the block as it were, splashed onto the adiposity signal scene in 1994, and it is reviewed in other papers in this volume. Nonetheless, some comparisons with insulin are appropriate. Leptin quickly overshadowed insulin as the adiposity hormone of choice worth pursuing in many laboratories, in part because it is secreted from adipocytes themselves (face validity), in part because, unlike the case with insulin, it could be given systemically with few adverse side effects such as hypoglycemia (practicality), and in part because pharmaceutical and biotech companies vigorously pursued it (economics). First described in 1994, leptin has proven to be a key metabolic protein that has actions throughout the body. Most importantly for the present discussion, and analogous to what occurs with insulin, plasma leptin levels are directly correlated with adiposity, circulating leptin is transported into the CNS via a saturable process, and leptin receptors exist in many brain areas including the ARC. Within the brain, leptin has many actions including reducing food intake and increasing energy expenditure, and its prolonged administration causes the loss of body fat and body weight. A prominent current hypothesis is that leptin, being secreted in proportion to total body adiposity, is an important conveyor of overall nutritional status to the brain. The lack of sufficient leptin is considered to indicate depleted fat stores and to reduce or turn off functions that require adequate energy stores to be successful (such as reproduction). Animals with ineffective leptin signaling (either because they do not synthesize leptin, ob=ob 'obese' mice; or because they have defective leptin receptors, db=db 'diabetic' mice and fa=fa 'fatty' Zucker rats) are characterized by hyperphagia and obesity. Hence, leptin, like insulin, satisfies the criteria to be an adiposity signal to the brain. 19, 20 The leptin receptor is in the cytokine receptor family, and it exists in many natural forms in the brain. Although it is a simplification, the leptin receptor can be considered to have two functional parts. The extracellular domain recognizes and interacts with extracellular leptin and is identical for all known leptin receptors. The intracellular domain, when appropriately activated, causes certain cellular events to be initiated. It is variations in the length of the internal domain that determine the type of action leptin exerts on a cell. All intracellular forms of the leptin receptor activate the Janus kinases (JAK-STAT pathway of tyrosine protein kinases). The longest form, termed OB-Rb, which is predominantly found in the hypothalamus, including the ARC, is recognized to have the capacity to activate several intracellular signaling pathways in addition to JAK-STAT and thereby to activate transcription factors.
Soon after its discovery, it was reported that, when mice are administered exogenous leptin into the brain, they reduce their food intake and body weight. Our laboratory replicated this phenomenon in rats and found that leptin exerts this effect without causing signs of illness. We also mapped the location of OB-Rb in the brain and determined where leptin administration elicits c-Fos expression. We also found that leptin acts in the ARC to reduce NPY synthesis and to stimulate POMC synthesis, and we proposed a model based upon the opposing actions of anabolic neuropeptides such as NPY and Agouti-related peptide (AgRP) and catabolic neuropeptides such as a-melanocyte stimulating hormone (a-MSH). We also reported that the ability of leptin to reduce food intake critically depends upon 'downstream' stimulation of activity at melanocortin-4 (MC-4) receptors since the administration of mixed MC3=4 antagonists or specific MC-4 antagonists attenuates leptin's ability to reduce food intake and induce fos activity in the paraventricular nuclei (PVN). Like others, we also found that the administration of MC-4 agonists reduces food intake and body weight. Reviews of this work are in other articles in this volume.
Similarities and differences among adiposity signals
It is worth considering why there should be more than one adiposity signal to the brain. The simple answer is that redundancy is the rule rather than the exception in the control of energy homeostasis. Nonetheless, insulin reflects different fat stores, genders and risk factors for developing type-2 diabetes mellitus and various cardiovascular problems, than does leptin. That is, whereas the levels of insulin and leptin both signal the degree of adiposity to the brain, each has important other functions throughout the body. Insulin is a major controller of the levels and utilization of glucose throughout most of the body. Low circulating leptin and the resultant decrease of leptin signaling have been hypothesized to regulate many vital systems when animals are severely under fed and have low body fat. There are other fundamental differences. For one, the secretion of insulin is adjusted in response to every acute change of metabolism. Its levels increase during meals or when glucose is elevated for some other reason, and they decrease during stress and exercise. The half-life of insulin in the blood (2 -3 min) is consistent with its role as a minute-to-minute indicator of ongoing metabolism, and all of its fluctuations are directly proportional to total body fat. Leptin is secreted from adipocytes in direct proportion to the amount of stored fat. However, the actual stimulus is related more to the metabolic activity of the fat cell than to actual fat storage such that dissociations can occur between stored fat and leptin release, particularly during a fast. Nonetheless, under normal conditions and with a half-life of 45 min, plasma leptin levels are a reliable and rather stable indicator of body fat. Hence, insulin levels reflect the interaction of ongoing metabolic processes and body adiposity, whereas leptin levels reflect the activity of adipose cells more directly.
Another difference is that insulin secretion reflects the amount of visceral white adipose tissue, whereas leptin secretion reflects total fat mass and especially subcutaneous fat. This is potentially very important with regard to the message conveyed to the brain since visceral fat is a greater risk factor for the metabolic complications associated with obesity than is subcutaneous fat. Elevated visceral fat is associated with an increased incidence of insulin resistance, type 2 diabetes mellitus, hypertension, cardiovascular disease and certain cancers. Hence, while the circulating levels of leptin and insulin each convey specific information as to the distribution of fat, the combination of the two conveys additional information about the total fat mass of the body.
